Multimodal Ultrasound Model Based on the Left Gastric Vein in B-Viral Cirrhosis: Noninvasive Prediction of Esophageal Varices

Xinzhi Xu, MS1, Ying Jin, MD, PhD2, Yuanqiang Lin, PhD1, Dongmei Hu, MS3, Yaoyao Zhou, BS1, Dianqiu Li, MS1, Hui Wang, PhD1 and Chunxiang Jin, MD, PhD1

OBJECTIVES: To establish and verify a simple noninvasive model based on the left gastric vein (LGV) to predict the grade of esophageal varices (EV) and high-risk EV (HEV), to facilitate clinical follow-up and timely treatment.

METHODS: We enrolled 320 patients with B-viral cirrhosis. All patients underwent endoscopy, laboratory tests, liver and spleen stiffness (SS), and ultrasonography. HEV were analyzed using the $\chi^2$ test/t test and logistic regression in the univariate and multivariate analyses, respectively. EV grades were analyzed using the variance/rank-sum test and logistic regression. A prediction model was derived from the multivariate predictors.

RESULTS: In the training set, multivariate analysis showed that the independent factors of different EV grades were SS, LGV diameter, and platelet count (PLT). We developed the LGV diameter-SS to PLT ratio index (LSPI) and LGV diameter/PLT models without SS. The area under the receiver operating characteristic curve of the LSPI for diagnosis of small EV, medium EV, large EV, and HEV was 0.897, 0.899, 0.853, and 0.954, respectively, and that of the LGV/PLT was 0.882, 0.890, 0.837, and 0.942, respectively. For the diagnosis of HEV, the negative predictive value was 94.07% when LSPI $< 19.8$ and the positive predictive value was 91.49% when LSPI $> 23.0$. The negative predictive value was 95.92% when LGV/PLT $< 5.15$, and the positive predictive value was 86.27% when LGV/PLT $> 7.40$. The predicted values showed similar accuracy in the validation set.

DISCUSSION: Under appropriate conditions, the LSPI was an accurate method to detect the grade of EV and HEV. Alternatively, the LGV/PLT may also be useful in diagnosing the varices when condition limited.

INTRODUCTION

Cirrhosis is the advanced stage of various liver diseases, and hepatitis B infection is one of the common causes of the condition in China. Portal hypertension (PH) is the main consequence of cirrhosis and the cause of ascites, hepatic encephalopathy, and esophageal varices (EV) (1,2).

The presence of EV denotes clinically significant PH, which is a landmark in the course of cirrhosis associated with decompensation and a high mortality rate. Approximately 7%–8% patients with compensated cirrhosis develop new EV annually, and 10%–12% of small EV can progress to medium/large EV after 1–2 years (3). Mortality rates as high as 20% have been reported because of progression of EV to variceal hemorrhage (4), and approximately 60% patients experience recurrence of bleeding within 1–2 years despite clinical treatment (5). In addition, the presence of EV might influence the outcomes of cirrhosis (6). Current guideline recommends endoscopy for all patients with cirrhosis; however, only 15%–25% of EV demonstrate a high risk of bleeding. Regular endoscopy for all patients would increase medical workload, as well as cause discomfort in asymptomatic patients. Furthermore, endoscopy is not a risk-free procedure. Therefore, an early, accurate, and repeatable noninvasive method is required for timely evaluation of EV.

Some guidelines recommend certain proposed novel noninvasive methods to predict EV (3,7). The left gastric vein (LGV) is directly related to the portal system and is a major vessel linked

1Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China; 2Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin, China; 3Department of Ultrasound, The Second Hospital of Jilin University, Changchun, Jilin, China.

Correspondence: Chunxiang Jin, MD, PhD. jincx722@jlu.edu.cn. Ying Jin, MD, PhD. E-mail: jinying0216@jlu.edu.cn.

Received June 25, 2020; accepted October 7, 2020; published online November 4, 2020

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology

Clinical and Translational Gastroenterology 2020;11:e00262. https://doi.org/10.14309/ctg.0000000000000262
to EV anatomi- cally and hemodynamically. It is difficult to iden- tify the LGV because of limitations of early ultrasonic instru- ments (8). However, advances in ultrasound technology have enabled detection of the LGV. Previous studies have reported that assessment of the LGV helped in diagnosis of high-risk EV (HEV) (9). Liver stiffness and spleen stiffness (LS and SS, respectively) have been researched widely; however, the parameter that is more closely related to EV remains unknown (10–13). Acoustic radi- ation force impulse (ARFI) imaging is a new method to assess tissue elasticity, which has demonstrated higher success rates than transient elastography.

To date, no research has attempted to establish a prediction model based on the LGV combined with other noninvasive tests to reflect the grade of EV. Follow-up of patients would be facilitated by rough evaluation of the EV grade, thereby en- abling prediction of the bleeding risk. The purpose of this study was to generate and validate the usefulness of a simple pre- diction model based on the LGV.

METHODS

Patients

Patients were recruited from the China-Japan Union Hospital between September 2016 and September 2018. Our Institutional Ethics Committee approved the study protocol (2018062808), and written informed consent was obtained from all patients.

According to the Agenzia Italiana del Farmaco criteria, cirrhosis is diagnosed based on at least one of the following clinical characteristics: esophageal and/or gastric varices on endoscopy, platelet count (PLT) <100 × 10^9/L, and/or ultra- sound signs of cirrhosis (polycyclic margins of the liver and/or splenomegaly). Laboratory investigations were performed to determine hepatitis B virus (HBV) infection. The Child-Pugh score was used to indicate the functional class of cirrhosis. The exclusion criteria were patients with (i) cirrhosis due to other causes (n = 26); (ii) right heart failure, myelodysplasia, hematological, or autoimmune disease (n = 5); (iii) portal vein or splenic vein thrombosis (n = 7), family history of thrombo- cytopenia, and liver cirrhosis with hepatocellular carcinoma (n = 12); (iv) history of digestive tract hemorrhage (≥15 days) (n = 8); (v) history of PH treatment such as splenectomy, transjugular intrahepatic portosystemic shunt, partial splenic embolization, or endoscopic treatment (n = 45); (vi) ARFI failure or unreliable measurement (n = 6); and (vii) intolerance to endoscopy (n = 6).

Endoscopic evaluation of EV

Endoscopy was performed by an experienced clinician (>1,000 examinations) using the OLYMPUS SEV1S1 LUCERA CV-260SL instrument. The EV were divided into 3 groups based on the UK guidelines (14): (i) collapse on inflation of the esophagus with air (grade I, small EV), (ii) varices between grades 1 and 3 (grade II, medium EV), and (iii) large varices that occlude the lumen (grade III, large EV). High-risk EV were considered if any one of the following endoscopic features was met: (i) beaded or tumor-like EV; (ii) red-colored EV; (iii) EV with clots; or (iv) EV with the maximal diameter >0.5 cm (7).

Ultrasound examination

Ultrasound was performed after 8–12 hours of strict fasting. The ultrasound doctor was blinded to the results of the endoscopy. Conventional ultrasound and ARFI imaging were performed using the Siemens Acuson S2000 system. The oblique diameter of the right lobe of the liver, spleen thickness, and spleen diameter (SD) were measured, and the degree of ascites was defined based on recent guidelines (15). The portal vein system was observed, and the collateral vessels were determined as described in the literature (13). Successful detection of the LGV was defined as identification of the vein on the B-mode image (8). The average of 3 valid measurements was considered, and the LGV flow volume (mL/min) was calculated as π × (diameter/2)^2 × 60 × velocity. LS and SS were measured by ARFI (m/s). Each parameter was repeatedly measured 10 times, and the average was calculated. Failure of ARFI imaging was defined as absence of valid shots, and unreliable measurements were defined as a median interquartile range greater than 30% or success rate less than 60%.

Statistical analyses

Statistical analyses were performed using SPSS 20.0 for Windows (SPSS, Chicago, IL) and MedCalc Software.

The data are expressed as X ± S. The analysis of the variance/ rank-sum test was used for comparison among multiple groups. The χ^2 test/ t test was used for comparison between 2 groups. Considering the endoscopy results as the gold standard, multivariate logistic re- gression analysis included variables of the univariate logistic re- gression analysis. There were no significant differences in the basic character-istics between patients in the training and validation sets.

RESULTS

Characteristics of patients in the training and validation sets

The characteristics of patients in the training and validation sets are shown in Table 1. A total of 435 patients were enrolled, and 115 were excluded based on the previously described criteria. Among the 179 patients in the training set (mean age: 52.66 years; 121 men), 126 patients had EV (small, medium, and large EV, n = 42 each), and 59 had HEV. One hundred patients were graded as Child-Pugh class A (55.9%), 59 as class B (32.9%), and 20 as class C (11.2%).

There were no significant differences in the basic character-istics between patients in the training and validation sets.

Predictors of the EV grade in the training set

Table 2 shows the parameters with different grades of EV in the training set. First, univariate analysis was performed to evaluate variables related to the grade of EV, which were then entered into a stepwise logistic regression model. Finally, the LGV diameter (P < 0.001, odds ratio [OR] 4.196, 95% confidence interval [CI] 2.737–6.432), SS (P = 0.048, OR 3.122, 95% CI 1.026–9.501), and PLT (P = 0.037, OR 0.990, 95% CI 0.981–1.000) were identified as independent predictors of the grade of EV.
The AUROC of the LGV diameter for different EV grades was 0.900 (small, 95% CI 0.838–0.963), 0.759 (medium, 95% CI 0.652–0.866), and 0.814 (large, 95% CI 0.715–0.912). Similarly, the values for SS were 0.715 (small, 95% CI 0.613–0.818), 0.630 (medium, 95% CI 0.509–0.752), and 0.663 (large, 95% CI 0.546–0.780). AUROCs for the PLT were 0.811 (small, 95% CI 0.724–0.898), 0.611 (medium, 95% CI 0.489–0.732), and 0.789 (large, 95% CI 0.691–0.886).

| Table 1: Baseline patient characteristics of the training and validation sets and comparisons between the 2 groups |
|-------------------------------------------------|-------------------------------------------------|---|
| Variable | Training set (n = 179) | Validation set (n = 141) | P-value |
| Basic information | | | |
| Age (yr) | 52.66 ± 12.30 | 54.85 ± 9.83 | 0.085 |
| Sex (male) | 121 (67.6%) | 72 (65.2%) | 0.721 |
| BMI (kg/m²) | 23.20 ± 2.80 | 21.78 ± 1.88 | <0.001 |
| Child-Pugh classification (A/B/C) | 100/59/20 | 65/57/19 | 0.222 |
| Ultrasound measurement | | | |
| RL | 11.16 ± 1.55 | 11.38 ± 1.50 | 0.202 |
| LD | 6.51 ± 1.42 | 6.72 ± 1.48 | 0.020 |
| LT | 6.34 ± 1.06 | 6.70 ± 1.74 | 0.185 |
| Portal vein diameter (cm) | 1.33 ± 0.23. | 1.34 ± 0.18 | 0.526 |
| Portal vein velocity (cm/s) | 14.27 ± 3.61 | 14.33 ± 2.21 | 0.864 |
| Spleen thickness | 4.46 ± 0.99 | 4.41 ± 0.94 | 0.635 |
| Spleen diameter | 12.37 ± 2.89 | 12.40 ± 2.88 | 0.921 |
| Spleen vein diameter (cm) | 0.98 ± 0.24 | 1.00 ± 0.21 | 0.589 |
| Spleen vein velocity (cm/s) | 16.80 ± 4.31 | 15.98 ± 2.91 | 0.053 |
| LGV diameter (mm) | 4.87 ± 1.67 | 4.98 ± 1.57 | 0.561 |
| LGV velocity (cm/s) | 11.09 ± 2.37 | 11.33 ± 1.34 | 0.288 |
| Blood test | | | |
| AST (IU/L) | 56.53 ± 89.63 | 57.42 ± 39.54 | 0.913 |
| ALT (IU/L) | 49.08 ± 103.36 | 43.76 ± 34.52 | 0.558 |
| ALP (IU/L) | 111.23 ± 61.36 | 116.94 ± 62.59 | 0.413 |
| GGT (IU/L) | 90.38 ± 162.37 | 81.02 ± 111.18 | 0.559 |
| LAP (U/L) | 40.94 ± 17.62 | 42.96 ± 17.55 | 0.309 |
| GLDH (U/L) | 13.05 ± 23.87 | 16.18 ± 32.67 | 0.323 |
| LDH (IU/L) | 228.15 ± 125.14 | 262.79 ± 180.46 | 0.044 |
| T-bil (µmol/L) | 26.32 ± 30.74 | 25.71 ± 20.98 | 0.842 |
| TBA (µmol/L) | 15.85 ± 19.90 | 26.75 ± 53.41 | 0.013 |
| ALB (g/L) | 37.41 ± 7.15 | 36.36 ± 7.91 | 0.216 |
| PT (s) | 14.52 ± 2.76 | 14.36 ± 2.83 | 0.612 |
| PLT (10⁹/L) | 121.81 ± 81.66 | 121.26 ± 58.38 | 0.947 |
| EV, n (%) | | | 0.951 |
| None | 53 (29.6%) | 43 (30.5%) | |
| Small | 42 (23.5%) | 32 (22.7%) | |
| Medium | 42 (23.5%) | 36 (25.5%) | |
| Large | 42 (23.5%) | 30 (21.3%) | |
| High-risk EV | 59 (34.1%) | 44 (31.2%) | |
| Liver stiffness (m/s) | 2.04 ± 0.54 | 2.07 ± 0.34 | 0.534 |
| Spleen stiffness (m/s) | 2.82 ± 0.47 | 2.91 ± 0.33 | 0.065 |

ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; EV, esophageal varices; GGT, γ-glutamyl transferase; GLDH, glutamine dehydrogenase; LAP, leucine aminopeptidase; LD, left lobe of liver diameter; LDH, lactate dehydrogenase; LGV, left gastric vein; LT, left lobe of liver thickness; PT, prothrombin time; PLT, platelet count; RL, right lobe of liver oblique diameter; T-bil, total bilirubin; TBA, total bile acid.
We further analyzed the relationship among AUROC and the grade of EV and found that the severity significantly correlated with widening of the LGV diameter (r = 0.794, P < 0.001), increase in SS (r = 0.573, P < 0.001), and a reduction in the PLT (r = −0.689, P < 0.001).

Predictors of HEV in the training set
Table 3 shows the parameters of patients with HEV in the training set. The method of analysis was as described above. The LGV diameter, SS, and PLT were confirmed as independent predictors of HEV.
The AUROCs were 0.942 (95% CI 0.896–0.971) for the LGV diameter, 0.826 (95% CI 0.763–0.879) for SS, and 0.873 (95% CI 0.816–0.918) for PLT.

Novel formula for prediction of HEV and grade of EV
We devised a new formula, the LGV diameter-SS to PLT ratio index (LSPI), including the LGV diameters and SS (OR = 1 each) as the numerator, and PLT (OR < 1) as the denominator to amplify the effect of each factor during the progression of EV.

\[
\text{LSPI} = \frac{\text{LGV diameters (mm)} \times \text{SS (m/s)}}{\text{PLT (x \times 10^9/L)}}
\]

Simultaneously, we also considered that measurement of SS might not be possible in some areas. To achieve comprehensive clinical outcomes, we removed the ARFI data and reanalyzed the remaining data. The LGV diameters (OR = 4.375 > 1, \( P < 0.001 \)) and PLT (OR = 0.989 < 1, \( P = 0.016 \)) were the independent factors for the analysis to derive the formula:

### Table 3. Comparisons and uni/multivariate analysis of variables according to presence of high-risk EV in the training set

| Variable                  | Patient without HEV (n = 120) | Patient with HEV (n = 59) | Univariate analysis (\( P \) value) | Multivariate analysis (OR (95% CI) \( P \) value) |
|---------------------------|-------------------------------|----------------------------|-------------------------------------|-----------------------------------------------|
| Basic information         |                               |                            |                                     |                                               |
| Age (yr)                  | 50.76 ± 12.89                 | 56.53 ± 10.03              | 0.004                               | 0.956 (0.875–1.044) \( 0.314 \)              |
| Sex (male/female)         | 39/81                         | 19/40                      | 0.968                               |                                               |
| BMI (kg/m²)               | 23.25 ± 2.80                  | 23.12 ± 2.83               | 0.983                               |                                               |
| Child-Pugh classification | 89/26/5                       | 11/33/15                   | <0.001                              |                                               |
| (A/B/C)                   |                               |                            |                                     |                                               |
| Ultrasound measurement    |                               |                            |                                     |                                               |
| RL                        | 11.13 ± 1.54                  | 11.22 ± 1.59               | 0.716                               |                                               |
| LD                        | 6.52 ± 1.40                   | 6.35 ± 1.11                | 0.983                               |                                               |
| LT                        | 6.33 ± 1.04                   | 6.35 ± 1.12                | 0.914                               |                                               |
| Portal vein diameter (cm) | 1.27 ± 0.23                   | 1.44 ± 0.20                | <0.001                              | 0.716 (0.013–41.017) \( 0.872 \)              |
| Portal vein velocity (cm/s)| 14.86 ± 3.35                  | 13.07 ± 3.85               | 0.002                               | 1.001 (0.817–1.226) \( 0.994 \)               |
| Spleen thickness          | 4.08 ± 0.69                   | 5.22 ± 1.07                | <0.001                              | 1.711 (0.444–6.589) \( 0.435 \)               |
| Spleen diameter           | 11.25 ± 2.06                  | 14.64 ± 3.02               | <0.001                              | 0.923 (0.582–1.463) \( 0.733 \)               |
| Spleen vein diameter (cm) | 0.91 ± 0.19                   | 1.15 ± 0.24                | <0.001                              | 2.529 (0.021–297.595) \( 0.703 \)             |
| Spleen vein velocity (cm/s)| 14.82 ± 3.10                  | 14.32 ± 3.20               | 0.316                               |                                               |
| LGV diameter (mm)         | 4.02 ± 0.90                   | 6.59 ± 1.56                | <0.001                              | 13.649 (3.873–48.108) \( <0.001 \)            |
| LGV velocity (cm/s)       | 10.59 ± 2.13                  | 12.10 ± 2.54               | <0.001                              | 1.131 (0.776–1.648) \( 0.521 \)               |
| Liver stiffness (m/s)     | 1.90 ± 0.51                   | 2.33 ± 0.47                | <0.001                              | 0.463 (0.074–2892) \( 0.410 \)                |
| Spleen stiffness (m/s)    | 2.66 ± 0.42                   | 3.16 ± 0.37                | <0.001                              | 10.412 (0.907–119.544) \( 0.060 \)            |
| Blood test                |                               |                            |                                     |                                               |
| AST                       | 54.30 ± 103.88                | 61.07 ± 49.84              | 0.642                               |                                               |
| ALT                       | 50.94 ± 121.74                | 45.28 ± 48.55              | 0.734                               |                                               |
| ALP (IU/L)                | 105.70 ± 39.52                | 122.48 ± 90.32             | 0.109                               |                                               |
| GGT (IU/L)                | 84.11 ± 122.46                | 103.48 ± 223.37            | 0.469                               |                                               |
| LAP (IU/L)                | 40.39 ± 16.07                 | 42.05 ± 20.53              | 0.553                               |                                               |
| GLDH (IU/L)               | 14.00 ± 27.89                 | 11.11 ± 12.09              | 0.464                               |                                               |
| LDH (IU/L)                | 214.51 ± 77.40                | 255.83 ± 186.03            | 0.056                               |                                               |
| T-bil (µmol/L)            | 22.49 ± 25.53                 | 34.10 ± 38.36              | 0.047                               | 1.006 (0.975–1.039) \( 0.696 \)               |
| TBA (µmol/L)              | 13.58 ± 19.49                 | 20.40 ± 20.12              | 0.042                               | 0.977 (0.931–1.025) \( 0.346 \)               |
| ALB (g/L)                 | 39.35 ± 6.69                  | 33.30 ± 6.43               | <0.001                              | 1.081 (0.955–1.222) \( 0.217 \)               |
| PT (s)                    | 13.66 ± 2.18                  | 16.28 ± 2.99               | <0.001                              | 0.905 (0.752–1.089) \( 0.290 \)               |
| PLT (x \times 10^9/L)     | 146.10 ± 86.41                | 70.37 ± 33.68              | <0.001                              | 0.970 (0.943–0.998) \( 0.036 \)               |

CI, confidence interval; EV, esophageal varices; HEV, high-risk esophageal varices; LGV, left gastric vein; OR, odds ratio; PLT, platelet count.
individual factors SS ($P = 0.0003$, $P = 0.0031$, respectively) and PLT (both $P = 0.0004$). The AUROCs of the LGV diameter, LSPI, and LGV/PLT were not statistically different. The AUROCs of the LSPI and LGV/PLT in the medium EV group were significantly higher than the individual factors; the LSPI and LGV/PLT have no statistical difference. There was no significant difference between the formulas and individual factors in the large EV group, which could be due to the accompanying spleen hyperactivity, making the PLT and SS highly predictable, but unstable. The LGV/PLT cutoff values to predict small, medium, and large EV were 3.04, 4.57, and 6.35, respectively, whereas those of the LSPI were 9.0, 10.8, and 19.9, respectively. The LSPI and LGV/PLT values in the validation group also showed excellent diagnostic efficacy. The AUROCs of the LSPI for small, medium, and large EV were 0.999, 0.954, and 0.985, respectively, and for the LGV/ PLT, AUROCs were 0.997, 0.952, and 0.985, respectively.

The AUROCs of the LGV diameter, SS, PLT, LSPI, and LGV/PLT for predicting HEV in the training set were 0.942, 0.826, 0.873, 0.954, and 0.942, respectively. The LGV diameter and the formulas showed satisfactory diagnostic efficacy, and the LSPI was significantly superior to the former parameters ($P < 0.05$). For further verification, we compared the formulas proposed in our study with previous formulas, aspartate aminotransferase/alanine aminotransferase ratio (0.640, 95% CI 0.565–0.710), aspartate aminotransferase-to-platelet ratio index [APRI]) (0.784, 95% CI 0.716–0.842), ARFI-SD to platelet ratio score (ASPS) (0.891, 95% CI 0.836–0.933), and SD/PLT (0.882.95% CI 0.825–0.925), and found that our formulas were superior ($P < 0.05$). The same results were obtained in the validation group.

### Determination and verification of the cutoff value for detection of HEV

Table 6 shows the sensitivity, specificity, and PPV of the cutoff values obtained from the ROC curves, for prediction of HEV in the training set. Two cutoff values of the LGV/PLT were chosen to predict HEV. LGV/PLT values $<5.15$ indicated that patients

### Table 5. Formula and independent factor for predicting EV grade and HEV in the training set and the validation set

| Training set | Prediction of small EV AUROC (95% CI) | Prediction of medium EV AUROC (95% CI) | Prediction of large EV AUROC (95% CI) | Prediction of high-risk EV AUROC (95% CI) |
|--------------|--------------------------------------|---------------------------------------|--------------------------------------|------------------------------------------|
| Spleen stiffness | 0.715 (0.613–0.818) | 0.630 (0.509–0.752) | 0.663 (0.546–0.780) | 0.826 (0.761–0.891) |
| Platelets counts | 0.811 (0.724–0.898) | 0.611 (0.489–0.732) | 0.789 (0.691–0.886) | 0.873 (0.817–0.929) |
| LGV diameter | 0.900 (0.838–0.963) | 0.759 (0.652–0.866) | 0.814 (0.715–0.912) | 0.942 (0.901–0.982) |
| LSPI | 0.897 (0.832–0.962) | 0.899 (0.845–0.939) | 0.853 (0.772–0.933) | 0.954 (0.926–0.983) |
| LGV/PLT | 0.882 (0.813–0.951) | 0.890 (0.834–0.932) | 0.837 (0.751–0.923) | 0.942 (0.909–0.974) |

| Validation set | Prediction of small EV AUROC (95% CI) | Prediction of medium EV AUROC (95% CI) | Prediction of large EV AUROC (95% CI) | Prediction of high-risk EV AUROC (95% CI) |
|----------------|--------------------------------------|---------------------------------------|--------------------------------------|------------------------------------------|
| Spleen stiffness | 0.996 (0.989–1.000) | 0.707 (0.576–0.837) | 0.838 (0.738–0.938) | 0.881 (0.825–0.937) |
| Platelets counts | 0.967 (0.926–1.000) | 0.660 (0.530–0.790) | 0.879 (0.795–0.963) | 0.908 (0.859–0.957) |
| LGV diameter | 0.991 (0.972–1.000) | 0.930 (0.860–1.000) | 0.986 (0.966–1.000) | 0.943 (0.909–0.977) |
| LSPI | 0.999 (0.997–1.000) | 0.954 (0.925–0.983) | 0.985 (0.964–1.000) | 0.946 (0.910–0.982) |
| LGV/PLT | 0.997 (0.991–1.000) | 0.952 (0.922–0.981) | 0.985 (0.963–1.000) | 0.944 (0.907–0.981) |

AUROC, area under the receiver operating characteristic curve; CI, confidence interval; EV, esophageal varices; HEV, high-risk esophageal varices; LGV, left gastric vein; LSPI, LGV diameter-SS to PLT ratio index; PLT, platelet count.
without HEV could be correctly excluded (95.92% NPV), and these low-risk patients could avoid endoscopy. Likewise, LGV/PLT values >7.4 indicated accuracy in the diagnosis of HEV (86.27% PPV), signifying the need for primary prophylaxis and endoscopy.

Similarity, 2 cutoffs of the LSPI were chosen to predict HEV. When the LSPI values were <19.8, 94.07% of the patients without HEV were accurately excluded. Likewise, when the values were >23.0, 91.49% of patients with HEV were diagnosed correctly.

We verified the above cutoff values in the validation set (Table 7), and the formulas showed excellent diagnostic capabilities. The AUROCs of the LGV/PLT of small EV, medium EV, large EV, and HEV were 0.900, 0.759, 0.814, and 0.942, respectively. The LGV diameter was satisfactory for the diagnosis of HEV (86.27% PPV), positive predictive value.

Table 6. Diagnostic accuracy of LGV diameter, LGV/PLT, and LSPI for prediction of high-risk EV in the training set

| LGV cutoff values | 5.1 mm | 5.6 mm |
|------------------|--------|--------|
| NPV (%)          | 93.69 (86.98–97.21) | 87.97 (80.92–92.75) |
| PPV (%)          | 76.47 (64.35–85.56) | 93.48 (81.07–98.30) |
| Sensitivity (%)  | 88.14 (76.46–94.70) | 72.88 (59.51–83.26) |
| Specificity (%)  | 86.67 (78.96–91.95) | 97.50 (92.32–99.35) |
| Interpretation   | Absence of HEV | Presence of HEV |

| LGV/PLT cutoff values | 5.15 | 7.40 |
|-----------------------|------|------|
| NPV (%)               | 95.92 (89.28–98.68) | 88.28 (81.11–93.07) |
| PPV (%)               | 67.90 (56.49–77.60) | 86.27 (56.49–77.60) |
| Sensitivity (%)       | 93.22 (82.73–97.81) | 74.58 (61.30–84.63) |
| Specificity (%)       | 78.33 (69.69–85.12) | 94.17 (87.92–97.42) |
| Interpretation        | Absence of HEV | Presence of HEV |

| LSPI cutoff values    | 19.8 | 23.0 |
|----------------------|------|------|
| NPV (%)              | 94.07 (87.72–97.38) | 87.88 (81.78–92.70) |
| PPV (%)              | 85.25 (73.33–92.62) | 91.49 (78.73–97.24) |
| Sensitivity (%)      | 88.14 (76.43–94.70) | 72.88 (59.50–83.26) |
| Specificity (%)      | 92.50 (85.85–96.30) | 96.67 (91.17–98.93) |
| Interpretation       | Absence of HEV | Presence of HEV |

The diameter, flow velocity, and flow volume of the LGV increased with the grade of EV and were significantly higher in the HEV group. The AUROCs of the LGV diameter of small EV, medium EV, large EV, and HEV were 0.900, 0.759, 0.814, and 0.942, respectively. The LGV flow volume also showed good diagnostic efficacy, while the flow velocity was relatively poor (Table 8). There was no statistical difference between the LGV diameter and flow volume (P = 0.7477) in the diagnosis of HEV, and the flow velocity was lower than the 2 values (P < 0.001). Moreover, calculation of LGV flow volume is cumbersome; therefore, we focused on the LGV diameter.

Table 7. Diagnostic accuracy of LGV diameter, LGV/PLT, and LSPI for prediction of high-risk EV in the validation set

| LGV cutoff values | 5.1 mm | 5.6 mm |
|------------------|--------|--------|
| NPV (%)          | 91.01 (82.57–95.76) | 85.32 (76.96–91.12) |
| PPV (%)          | 69.23 (54.74–80.88) | 87.50 (70.07–95.92) |
| Sensitivity (%)  | 81.82 (66.76–91.29) | 63.64 (47.74–77.17) |
| Specificity (%)  | 83.51 (74.29–89.99) | 95.88 (89.18–98.67) |
| Interpretation   | Absence of HEV | Presence of HEV |

| LGV/PLT cutoff values | 5.15 | 7.40 |
|-----------------------|------|------|
| NPV (%)               | 95.12 (87.31–98.43) | 87.04 (78.88–92.48) |
| PPV (%)               | 67.80 (54.24–79.03) | 90.91 (74.53–97.62) |
| Sensitivity (%)       | 90.81 (77.42–97.05) | 68.18 (52.29–80.93) |
| Specificity (%)       | 80.41 (70.85–87.51) | 96.91 (90.58–99.20) |
| Interpretation        | Absence of HEV | Presence of HEV |

| LSPI cutoff values    | 19.8 | 23.0 |
|----------------------|------|------|
| NPV (%)              | 90.10 (82.13–94.89) | 86.26 (78.00–91.84) |
| PPV (%)              | 85.00 (69.48–93.75) | 90.63 (73.83–97.55) |
| Sensitivity (%)      | 77.29 (61.78–88.01) | 65.91 (50.00–79.07) |
| Specificity (%)      | 93.81 (86.50–97.46) | 96.91 (90.58–99.20) |
| Interpretation       | Absence of HEV | Presence of HEV |

Hemodynamic assessment of the LGV to diagnose EV

The LGV is a major pathway that brings blood into the esophageal veins through the upper stomach (16); therefore, it plays an important role in predicting EV. The direction of the LGV flow should be hepatic under normal circumstances. The proportion of reverse direction flow increases with the grade of EV (normal vs small vs medium vs large, 15.1% vs 45.2% vs 73.8% vs 100%, respectively; P < 0.001). Reverse direction flow in the HEV group (59/59, 100%) was significantly higher than in the non-HEV group (36/120 30%; P < 0.001).

In the training set, the LGV diameter was 2.0–11.6 mm, flow velocity was 67–192 cm/s, and flow volume was 14.7–1,033.1 mL/min.

DISCUSSION

HBV infection is one of the common causes of cirrhosis in China. Approximately 200 million people worldwide have HBV infection, and approximately 1.2 million people die annually because of cirrhosis and associated complications (17). EV bleeding is one of the main causes of death. Current guidelines recommended screening all patients with cirrhosis by endoscopy (3,14); however, this may be hampered by lack of compliance especially because of the need for periodic repetition. Moreover, endoscopy is an invasive, expensive, and uncomfortable procedure.
procedure and is not risk-free. Therefore, it is imperative to establish an economic, convenient, and noninvasive prediction system for EV.

Although several studies have been conducted on noninvasive tests to predict EV, our research has many advantages. First, we have focused on the LGV and are the first to combine it with other noninvasive tests.

**Figure 1.** Prediction and management system of esophageal varices in patients with cirrhosis.

| Table 8. The diagnostic ability of LGV hemodynamics to identify EV |
|---------------------------------------------------------------|
| **Value** | **P value** | **AUROC (95% CI)** | **Cutoff value** | **Sensitivity (%)** | **Specificity (%)** |
|---|---|---|---|---|---|
| **LGV flow direction** (forward/bidirectional/reverse) | | | | | |
| None | 42/8/3 | <0.001 | | | |
| Small EV | 11/12/19 | | | | |
| Medium EV | 5/6/12 | | | | |
| Large EV | 0/0/42 | | | | |
| Non-HEV | 58/26/36 | <0.001 | | | |
| HEV | 0/0/59 | | | | |
| **LGV diameter (mm)** | | | | | |
| None | 3.38 ± 0.73 | <0.001 | 0.900 (0.838–0.963) | 4 mm | 78.57 | 90.57 |
| Small EV | 4.48 ± 0.55 | | 0.795 (0.652–0.866) | 5 mm | 59.52 | 83.33 |
| Medium EV | 5.13 ± 1.04 | | 0.814 (0.715–0.912) | 6.5 mm | 61.90 | 97.62 |
| Large EV | 6.87 ± 1.72 | | | | | |
| Non-HEV | 4.02 ± 0.90 | <0.001 | 0.942 (0.896–0.971) | 5.3 mm | 83.05 | 94.17 |
| HEV | 6.59 ± 1.56 | | | | | |
| **LGV velocity (cm/s)** | | | | | |
| None | 10.02 ± 1.85 | <0.001 | 0.583 (0.463–0.704) | 10.2 cm/s | 59.52 | 66.04 |
| Small EV | 10.46 ± 1.95 | | 0.580 (0.571–0.799) | 11.4 cm/s | 59.52 | 73.81 |
| Medium EV | 11.93 ± 2.18 | | 0.524 (0.398–0.649) | 14.9 cm/s | 19.05 | 95.24 |
| Large EV | 12.21 ± 2.77 | | | | | |
| Non-HEV | 10.59 ± 2.13 | <0.001 | 0.682 (0.609–0.750) | 11.1 cm/s | 67.80 | 65.83 |
| HEV | 12.10 ± 2.54 | | | | | |
| **LGV flow volume (mL/min)** | | | | | |
| None | 57.0 ± 32.4 | <0.001 | 0.881 (0.813–0.949) | 67.1 | 88.10 | 75.47 |
| Small EV | 100.3 ± 30.6 | | 0.800 (0.700–0.899) | 140.1 | 61.90 | 90.48 |
| Medium EV | 155.9 ± 71.9 | | 0.793 (0.694–0.892) | 195.2 | 69.05 | 88.10 |
| Large EV | 295.1 ± 189.7 | | | | | |
| Non-HEV | 86.3 ± 44.2 | <0.001 | 0.938 (0.852–0.969) | 154.0 | 83.05 | 93.33 |
| HEV | 268.2 ± 170.4 | | | | | |

AUROC, area under the receiver operating characteristic curve; CI, confidence interval; EV, esophageal varices; HEV, high-risk esophageal varices; LGV, left gastric vein.
A study reported that the LGV gradually widened under CT with an increase in portal pressure (18). Zhang et al. (19) proposed that presence of lower esophageal Doppler signal, LGV hepatic venous blood flow, and paraumbilical vein recanalization could be considered HEV; however, the sensitivity was low. The LGV diameter has been considered valuable in predicting HEV (9,20). However, no research has focused on the relationship between the LGV and grade of EV. Our research not only predicted the grade of EV, but also HEV, which provided a general idea of the stage of the varices. Second, we combined multimodal ultrasound with laboratory investigations to achieve more stable and accurate diagnosis. LS and SS have been confirmed as promising indicators to predict EV in some studies; however, their diagnostic efficacy remains controversial. The Baveno VI Consensus (2015) reported that patients with an LS value <20 kPa and PLT >150,000 had a very low risk of treatment-requiring varices and could avoid screening endoscopy (7). This was verified by other studies (21,22); however, the endoscopy avoidance rate was not satisfactory (23). Salz et al. (24) reported that LS was closely related to EV; however, other studies reported that antiviral therapy decreased LS (25). Recent studies reported that SS was more closely related to PH than LS (10,11,26,27). A recent study (28) suggested that SS might be predictive of liver decompensation; however, other researchers disputed the view (12,29). In addition, recent studies showed that LS and SS jointly predicted EV and were more effective than the Baveno VI standard. These parameters reduced the need for endoscopy in nearly 50% of the patients and had high applicability (30,31). In our study, SS demonstrated higher diagnostic ability. Third, to enhance clinical applicability, we proposed the LSPI and LGV/PLT formulas, both of which demonstrated excellent diagnostic capability. These enabled prediction of HEV and the grade of EV, which facilitated rough assessment of the stage. Thus, by follow-up of the patients based on the guidelines, adverse reactions caused by premature use of drugs can be avoided (32).

SS reflected the grade of EV more effectively than LS, which may be attributed to direct reflection of the dynamic state of blood flow by SS (10). LS cannot reflect this aspect (33), and long-term antiviral treatment has been reported to affect LS (25). Thrombocytopenia may be due to hypersplenism caused by PH and an impaired immune system (34–36). Calvaruso et al. (37) reported that PLT was superior to LS in predicting large EV; however, both showed low AUROCs. The study reported that these noninvasive tests did not accurately detect small EV. However, in our study, PLT in cirrhosis patients without EV was high, which could be due to active treatment after the initial diagnosis. Further research is required to validate this assumption.

Presently, there are limited studies on the LGV, and the efficacy of the vein in predicting HEV is unclear (9,20). Our study provided information on this parameter and demonstrated that the diagnostic ability of the LGV diameter was significantly higher than the SS and PLT. Hemodynamics of the LGV also plays an important role in predicting EV. Reverse blood flow may be seen in the LGV with an increase in the portal pressure. Previous studies reported that the LGV flow velocity was related to HEV (9). In our study, although the velocity increased with an increase in the grade of EV, the diagnostic efficacy was low. Furthermore, we defined the cutoff value of the LGV diameter to predict HEV. This parameter could roughly estimate the EV grade and risk in the absence of laboratory results.

Both LSPI and LGV/PLT demonstrated excellent diagnostic accuracy in predicting EV, showing superiority to other noninvasive tests (13,38–41). The formulas were more prominent in small and medium EV, which compensated for the deficiencies of existing research. In the training set, diagnostic efficacy of the LSPI was significantly better than the LGV/PLT (AUROC 0.954 vs 0.942); therefore, we believe that the LSPI is more stable than the LGV/PLT. Hence, the LSPI would be ideal in suitable conditions; however, if measurement of SS was not possible, the LGV/PLT would be a good choice. Based on these results, it may be considered that the simple, noninvasive, and accurate system proposed in this study could predict the EV grade, diagnose HEV, and aid in patient follow-up and clinical decision-making.

This study has some limitations. First, we focused on patients with cirrhosis due to HBV alone. We aim to assess the applicability of the formulas in other forms of cirrhosis in future studies. Second, we did not conduct long-term follow-up to determine the incidence of bleeding events. Moreover, we did not exclude patients undergoing treatment that led to high PLT in the non-EV group. Finally, similar to the estimation of pulmonary artery pressure by echocardiography in liver transplant candidates (42,43), an accurate and safe method to noninvasively estimate portal pressure is important. We aim to conduct studies on this aspect.

In summary, we proposed the LSPI and LGV/PLT formulas, which showed excellent accuracy in diagnosis of the grade of EV and HEV. These results might lead to avoidance of unnecessary endoscopy. We hope that other studies will evaluate the reproducibility of the formulas for clinical application.

CONFLICTS OF INTEREST
Guarantor of the article: Xinzhi Xu, MS.
Specific author contributions: X.X.: collecting and interpreting data, drafting the manuscript. Y.J.: interpreting data, conducting the study.

Study Highlights

WHAT IS KNOWN
✓ Guidelines recommended screening all patients with cirrhosis by endoscopy.
✓ Most patients with cirrhosis do not have varices or have varices that do not require therapy.
✓ Many noninvasive methods have been proposed to predict HEV. However, their accuracy requires further analysis.
✓ Research has chiefly focused on predicting HEV but not on the EV grade.

WHAT IS NEW HERE
✓ Two novel LGV-based formulas, the LSPI and LGV/PLT, in which LSPI includes the LGV diameter, SS, and PLT and the LGV/PLT includes the LGV diameter and PLT. Both showed excellent diagnostic accuracy in predicting the grade of EV and HEV.
✓ LGV/PLT values < 5.15 facilitated exclusion of 95.92% of the patients without HEV. LGV/PLT values > 7.40 enabled correct diagnosis of 86.27% patients with HEV.
✓ LSPI values < 19.8 resulted in an NPV of 94.07%. A PPV of 91.49% was achieved at LSPI values > 23.0.
✓ The LSPI and LGV/PLT could be reliable noninvasive tools to predict HEV and EV grade.
✓ The LGV diameter could also be a promising tool to evaluate the EV grade and HEV.

TRANSLATIONAL IMPACT
✓ The simple formula based on LGV is more beneficial to clinically non-invasive and accurate diagnosis of esophageal varices in patients with liver cirrhosis and tracking at any time for timely intervention.
REFERENCES

1. de Franchis R. Non-invasive (and minimally invasive) diagnosis of oesophageal varices. J Hepatol 2008;49:520–7.
2. Tschochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749–61.
3. Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2017;65(1):310–35.
4. Levy MJ, Wong VW, Song LM, Song LM. EUS-guided angiography for gastric varices: Coil, glue, and sticky issues. Gastrointest Endosc 2013;78(5):722–5.
5. Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922–38.
6. Di Marco V, Calvaruso V, Ferraro D, et al. Effects of viral eradication in patients with hepatitis C virus and cirrhosis differ with stage of portal hypertension. Gastroenterology 2010;138:130–9.
7. de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743–52.
8. Matsutani S, furuse J, Ishii H, et al. Hemodynamics of the left gastric vein in portal hypertension. Gastroenterology 1993;105:513–8.
9. Maruyama H, Kobayashi K, Kiyono S, et al. Left gastric vein-based noninvasive test for esophageal varices: A same-day comparison of portal hemodynamic assessment with endoscopic appearance. Clin Transl Gastroenterol 2018;9:154.
10. Colechia A, Colli A, Casazza G, et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: A prospective study. J Hepatol 2014;60:1158–64.
11. Takuma Y, Nouso K, Morimoto Y, et al. Measurement of spleen stiffness by acoustic radiation force impulse imaging identifies cirrhotic patients with esophageal varices. Gastroenterology 2013;144:92–101.e2.
12. Bota S, Sporea I, Sirli R, et al. Spleen assessment by Acoustic Radiation Force Impulse Elastography (ARFI) for prediction of liver cirrhosis and portal hypertension. Med Ultrason 2010;12(3):213–7.
13. Kim BC, Kim SA, Park YN, et al. Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int 2007;27:969–76.
14. Tripathi D, Stanley AJ, Hayes PC, et al. UK guidelines on the management of varical haemorrhage in cirrhotic patients. Gut 2015;64:1680–704.
15. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397–417.
16. Maruyama H, Kamezaki H, Takahashi M, et al. The potential of transabdominal 3D color Doppler ultrasonography for diagnosis of gastric varices. J Clin Gastroenterol 2014;48(7):629–34.
17. Vodkin I, Patton H. Management of hepatitis B virus infection during pregnancy. Minerva Gastroenterol Dietol 2014;60:205–14.
18. Chen TW, Yang ZG, Wang QL, et al. Evaluation of gastric fundic and oesophageal varices by 64-row multidetector computed tomography before and after transjugular intrahepatic portosystemic shunt with concurrent left gastric vein embolization. Eur J Gastroenterol Hepatol 2010;22(3):289–95.
19. Zhang CX, Xu JM, Li JB, et al. Predict esophageal varices via routine transabdominal ultrasound: A design of classification analysis model. J Gastroenterol Hepatol 2016;31:194–9.
20. Konis K, Hino S, Koyama S, et al. How do we select an endoscopic treatment for esophageal varices on the basis of hemodynamic analysis using color Doppler endoscopic ultrasonography. Surg Laparosc Endosc Percutan Tech 2012;22(5):410–4.
21. Maurer JB, Brodkin E, Arnold F, et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. J Hepatol 2016;65(5):899–905.
22. Augustin S, Pons M, Genesca J. Validating the Baveno VI recommendations for screening varices. J Hepatol 2017;66:459–60.
23. Augustin S, Pons M, Maurice JB, et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology 2017;66(6):1980–8.
24. Salz P, Reiberger T, Ferlitsch M, et al. Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index. Ultraschall Med 2014;35(6):528–33.
25. Liang X, Xie Q, Tan D, et al. Interpretation of liver stiffness measurement—based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2-year prospective study. J Viral Hepat 2018;25:296–305.
26. Wong GL, Kwok R, Chan HL, et al. Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. J Dig Dis 2016;17:538–46.
27. Mazur R, Czerny M, Silicki J, et al. Clinical applications of spleen ultrasonography—a review. J Ultrasound 2018;18:37–41.
28. Meister P, Dechêne A, Büchter M, et al. Spleen stiffness differentiates between acute and chronic liver damage and predicts hepatic decompensation. J Clin Gastroenterol 2019;53(6):457–63.
29. Lim JK, Groszmann RJ. Transient elastography for diagnosis of portal hypertension in liver cirrhosis: Is there still a role for hepatic venous pressure gradient measurement? Hepatology 2007;45:1087–90.
30. Wong GLH, Kwok R, Hui AJ, et al. A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: A randomized trial. Liver Int 2018;38:636–44.
31. Wong GL-H, Liang LY, Kwok R, et al. Low risk of variceal bleeding in cirrhotic patients after varical screening stratified by liver/spleen stiffness. Hepatology 2019;70:971–81.
32. Ibrahim M, Mostafa I, Devière J. New developments in managing varical bleeding. Gastroenterology 2018;154:1964–9.
33. Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45:1290–7.
34. Giannini EG. Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006;23:1055–65.
35. Poynard T, Trabut JB, Ratziu V, et al. Prediction of esophageal varices with platelet count/spleen diameter ratio or platelets alone. Gut 2004;53:913–4.
36. Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol 2008;15(3):473–80.
37. Calvaruso V, Cacciola I, Anna L, et al. Is transient elastography needed for noninvasive assessment of high-risk varices? The REAL experience. Am J Gastroenterol 2019;114:1275–82.
38. Wai CT, Groensens JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26.
39. Sheff SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93:44–8.
40. Poynard T, Bedossa P. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAIVIR and CLINIVIR cooperative study groups. J Viral Hepat 1997;4:199–208.
41. Park Y, Kim SY, Park SY, et al. A novel model to predict esophageal varices in patients with compensated cirrhosis using acoustic radiation force impulse elastography. PLoS One 2015;10(3):e0121009.
42. Habash F, Gurram P, Almomani A, et al. Correlation between subjective hepatic stiffness measurement (LSSM) and liver fibrosis measured by transient elastography. J Med Ultrasonics 2013;40(1):52–7.
43. Desjardins JT, Maniciardi M, Svetlichnyy Y, et al. Noninvasive estimation of pulmonary vascular resistance improves portopulmonary hypertension screening in liver transplant candidates. Clin Transplant 2019;33:e13585.

Open Access This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.